Aligos Therapeutics Reports Strong Q4 2025 Results, Extends Cash Runway, and Advances Pipeline
Summary
Aligos Therapeutics announced strong Q4 2025 financial results with a significantly reduced net loss, an increased cash position of $77.8 million, and an extended cash runway into Q3 2026, alongside positive pipeline progress.
Key Events
-
Strong Q4 2025 Financial Performance
Reported a net loss of $(1.91) per share for Q4 2025, a substantial improvement from $(13.08) in Q4 2024, and significantly reduced full-year net loss to $(2.45) per share from $(20.94) in 2024.
-
Extended Cash Runway
Cash, cash equivalents, and investments totaled $77.8 million as of December 31, 2025, an increase from $56.9 million in 2024, and are expected to fund operations into the third quarter of 2026.
-
Pipeline Advancement in HBV
Completed planned enrollment for HBeAg- participants in the Phase 2 B-SUPREME study for pevifoscorvir sodium and advanced ALG-170675, a dual-mechanism ASO, into IND-enabling studies with partner funding for China.
-
Positive Preclinical Data for Obesity/MASH Program
ALG-055009 demonstrated synergistic weight loss in combination with incretin receptor agonists in preclinical models, with evaluation of out-licensing options ongoing.
Analysis
Aligos Therapeutics reported significantly improved financial results for Q4 and full year 2025, substantially reducing its net loss. The company's cash, cash equivalents, and investments increased to $77.8 million, providing sufficient funding into Q3 2026, a critical factor for a clinical-stage biotechnology company. This financial stability is complemented by positive pipeline advancements, including the completion of planned enrollment for a key Phase 2 study, the progression of a dual-mechanism ASO into IND-enabling studies, and promising preclinical data for an obesity/MASH candidate. The appointment of a Chief Commercial Officer also signals future strategic planning. This 8-K provides comprehensive details following an initial news report on the Q4 loss per share.
At the time of this filing, ALGS was trading at $7.20 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $42.2M. The 52-week trading range was $3.76 to $14.60. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.